Načítá se...
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial
BACKGROUND: Patients with advanced oesophageal cancer have a median survival of 3–6 months, and most require intervention for dysphagia. Self-expanding metal stent (SEMS) insertion is the most typical form of palliation in these patients, but dysphagia deterioration and re-intervention are common. T...
Uloženo v:
| Vydáno v: | Lancet Gastroenterol Hepatol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier B.V
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7955283/ https://ncbi.nlm.nih.gov/pubmed/33610215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2468-1253(21)00004-2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|